首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   48669篇
  免费   3621篇
  国内免费   94篇
耳鼻咽喉   424篇
儿科学   1536篇
妇产科学   1329篇
基础医学   6777篇
口腔科学   669篇
临床医学   5932篇
内科学   9407篇
皮肤病学   749篇
神经病学   4978篇
特种医学   1122篇
外国民族医学   8篇
外科学   5234篇
综合类   499篇
一般理论   49篇
预防医学   5786篇
眼科学   764篇
药学   3131篇
中国医学   31篇
肿瘤学   3959篇
  2023年   341篇
  2022年   592篇
  2021年   1305篇
  2020年   790篇
  2019年   1245篇
  2018年   1412篇
  2017年   1002篇
  2016年   1150篇
  2015年   1243篇
  2014年   1667篇
  2013年   2356篇
  2012年   3411篇
  2011年   3636篇
  2010年   1911篇
  2009年   1707篇
  2008年   3062篇
  2007年   3047篇
  2006年   2872篇
  2005年   2668篇
  2004年   2445篇
  2003年   2203篇
  2002年   2193篇
  2001年   758篇
  2000年   771篇
  1999年   659篇
  1998年   476篇
  1997年   389篇
  1996年   310篇
  1995年   299篇
  1994年   263篇
  1993年   225篇
  1992年   438篇
  1991年   390篇
  1990年   409篇
  1989年   362篇
  1988年   371篇
  1987年   344篇
  1986年   352篇
  1985年   297篇
  1984年   231篇
  1983年   200篇
  1982年   130篇
  1979年   166篇
  1978年   165篇
  1977年   141篇
  1975年   156篇
  1974年   184篇
  1973年   139篇
  1972年   140篇
  1971年   140篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und...  相似文献   
2.
3.
Despite orientation and mobility (O&M) being a significant factor determining quality of life of people with low vision or blindness, there are no gold standard measures or agreement on how to measure O&M performance. In the first part of this systematic review, an inventory of O&M outcome measures used by recent studies to assess the performance of orientation and/or mobility of adults with vision impairment (low vision and blindness) is presented. A wide variety of O&M outcome measures have been implemented in different fields of study, such as epidemiologic research and interventional studies evaluating training, assistive technology, vision rehabilitation and vision restoration. The most frequent aspect of outcome measures is efficiency such as time, distance, speed and percentage of preferred walking speed, followed by obstacle contacts and avoidance, and dis/orientation and veering. Other less commonly used aspects are target identification, safety and social interaction and self-reported outcome measures. Some studies employ sophisticated equipment to capture and analyse O&M performance in a laboratory setting, while others carry out their assessment in real-world indoor or outdoor environments. In the second part of this review, the appropriateness of implementing the identified outcome measures to assess O&M performance in clinical and functional O&M practice is evaluated. Nearly a half of these outcome measures meet all four criteria of face validity (either clinical or functional), responsiveness, reliability and feasibility and have the potential to be implemented in clinical or functional O&M practice. The findings of this review confirm the complicated and dynamic nature of O&M. Multiple measures are required in any evaluation of O&M performance to facilitate holistic assessment of O&M abilities and limitations of each individual.  相似文献   
4.
5.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.

Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.

Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.  相似文献   

6.
Metabolism describes the series of chemical reactions that are concerned with the provision of energy to biological systems. They may be divided into reactions involved in energy yield (catabolism: demand exceeds supply), and energy storage (anabolism: supply exceeds demand). Regulation of these pathways is critical for homeostasis, and derangements in metabolism are seen in a wide variety of pathological processes. Understanding metabolism is key to the treatment of many diseases, notably diabetes, as well as underpinning clinical nutritional support.  相似文献   
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号